A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection
A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection
The purpose of this study is to further assess the potency of PF-00868554, an HCV polymerase
 inhibitor, in subjects chronically infected with HCV by evaluating the antiviral activity of
 PF-00868554 in combination with current standard of care therapy, pegylated
 interferon-alpha2a (PEGASYS) and ribavirin (COPEGUS).
Inclusion Criteria:

 -  Treatment naive (no prior treatment with IFN-a +/- RBV regimens.

 -  Subjects who have discontinued IFN-a containing regimens after <2 weeks of therapy due
 to tolerability issues are considered treatment naive.

 -  HCV RNA > 100,000 IU/mL at screening.

 -  Genotype 1.

 -  A diagnosis of chronic HCV infection for at least 6 months.

 Exclusion Criteria:

 -  Evidence of acute or chronic infection with HIV or HBV.

 -  Exposure within the previous three months to an investigational anti-HCV agent.

 -  Evidence of severe or decompensated liver disease.

 -  Subjects with liver disease unrelated to HCV infection.